Skip to main content
MRNA logo

MRNA · Moderna, Inc. · Documents

Track MRNA — free
Market Cap
$83.68B
Shares
404.62M
Volume · Nov 17 8.28M Avg daily vol (3M) 21.89M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $1.94B down 39.9% 10-K filed Feb 20, 2026 Quarterly report FY2026 Q3 Revenue $1.31B up 29.2% 10-Q filed Nov 6, 2026 Latest results Raises 2026 revenue growth outlook to 15%–25% 8-K filed Nov 6, 2026 Earnings call Q3 2026 earnings call Held Nov 6, 2026
2026
Nov 16
Current report 8-K Events of Nov 9
Credit facility margins cut 0.75 points, maturity extended to 2031

Moderna amended its Ares Capital credit agreement, cutting term loan margins by 0.75 percentage points and extending maturity from November 24, 2030 to November 24, 2031.

Entered into a material agreement, New debt or off-balance-sheet obligation Read from the first part of this long document
2 source passages
The Amendment reduces the applicable interest rate margins for the initial term loans and delayed draw term loans by 0.75 percentage points, from 5.50% to 4.75% per annum for loans bearing interest at a forward-looking term rate derived from the Secured Overnight Funding Rate and from 4.50% to 3.75% per annum for loans bearing interest based on the base rate. The Amendment also extends the maturity date for those loans from November 24, 2030 to November 24, 2031. Open the document at this passage
Nov 13
Current report 8-K
Chief Legal Officer to retire with $1,628,300 severance

Moderna agreed that Chief Legal Officer Shannon Thyme Klinger will retire by March 31, 2027, with $1,628,300 in severance, COBRA support through September 30, 2028, and potential litigation payments of $2,500,000 and up to $5,500,000.

Director or officer change, or executive pay Read from the first part of this long document
5 source passages
On November 13, 2026, Moderna, Inc. (the “Company”) entered into a Transitional Services and Retirement Agreement (the “Retirement Agreement”) with Shannon Thyme Klinger, the Company’s Chief Legal Officer, that sets forth the terms of Ms. Klinger’s retirement from the Company. Subject to the terms and conditions of the Retirement Agreement, Ms. Klinger will continue employment with the Company until March 31, 2027 (the “Retirement Date”), transition her duties as requested by the Company, and be deemed to have resigned from all officer positions with the Company on the earlier of the Retirement Date and such date as is designated by the Company. Subject to the terms and conditions of the Retirement Agreement, Ms. Klinger will receive severance payments paid out in substantially equal biweekly installments over the twelve months following the Retirement Date in an aggregate amount of $1,628,300, representing twelve months of base salary plus her current annual target bonus. The Company will also pay Ms. Klinger’s COBRA premiums until September 30, 2028, subject to earlier termination if she becomes eligible for health coverage from a subsequent employer or ceases to be eligible for COBRA coverage. In addition, Ms. Klinger will be eligible to receive (i) $2,500,000 if the Company is the prevailing party upon the conclusion of all current and any related future litigation proceedings with Arbutus Biopharma Corporation and Genevant Sciences, GmbH and (ii) up to $5,500,000 subject to the result of the Company’s current and any related future litigation proceedings with Pfizer, Inc., BioNTech SE and related parties. Open the document at this passage
Nov 6
Earnings call
2026 revenue growth outlook raised to 15% to 25%

Moderna raised its 2026 revenue growth outlook to 15% to 25% from up to 10%. Its phase 3 melanoma therapy with pembrolizumab reduced recurrence or death risk by 42%, while quarterly revenue reached $1.3 billion.

4 source passages
Now let's turn to our financial framework for 2026. For total revenue, as I mentioned in my earlier remarks, we are improving our revenue outlook to a range of 15% to 25% growth, which exceeds our prior framework of up to 10% growth. The Moderna team delivered a great third quarter, generating $1.3 billion in revenues, representing 29% growth year over year. These remarkable results were observed at the first interim analysis of this large randomized phase 3 trial. Intis Moran plus pembrolizumab demonstrated a significant 42% reduction in the risk of recurrence or death compared with pembrolizumab alone. Open the document at this passage
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly profit reaches $162 million on $1,313 million revenue

Moderna reported revenue of $1,313 million and net income of $162 million for the quarter ended September 30, 2026. Nine-month net loss was $(1,963) million, and operating activities used $(2,715) million of cash.

Revenue $1.31B ▲ 29.2% Net income $162M Diluted EPS $0.38
Read from the first part of this long document
5 source passages
MODERNA, INC. Three Months Ended September 30, | | Nine Months Ended September 30, | 2026 | 2025 | 2026 | 2025 Total revenue | 1,313 | 1,016 | 1,847 | 1,266 Net income (loss) | 162 | (200) | (1,963) | (1,996) Net cash used in operating activities | (2,715) | (2,803) Open the document at this passage
Nov 6
Current report 8-K
Raises 2026 revenue growth outlook to 15%–25%

Moderna reported third-quarter revenue of $1.3 billion and net income of $162 million, raised its 2026 revenue growth outlook to 15%–25%, and expects year-end cash and investments of approximately $8.1 billion to $8.3 billion.

Financial results
5 source passages
Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates Total revenue for the third quarter of 2026 increased 29% to $1.3 billion, compared to $1.0 billion in the same period in 2025 Net income was $162 million for the third quarter of 2026, compared to a net loss of $(200) million in the third quarter of 2025, representing a $362 million improvement year-over-year. The Company now expects total revenue growth of 15% to 25% in 2026, exceeding its previous outlook of up to 10% growth. The Company now expects year-end 2026 cash and investments of approximately $8.1 billion to $8.3 billion, increased from its previous outlook of $4.7 billion to $5.2 billion. Open the document at this passage
Jul 31
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $145M ▲ 2.1% Net loss $782M Diluted EPS -$1.97
May 1
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $389M ▲ 260.2% Net loss $1.34B Diluted EPS -$3.40
Mar 16
Proxy statement DEF 14A Meeting May 6, 2026
Proxy statement AI summary on its way
Feb 20
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $1.94B ▼ 39.9% Net loss $2.82B Diluted EPS -$7.26
2025
Showing 1–50 of 197 documents
Key facts CIK 1682852 CUSIP 60770K107 13F (30d) 1065 filings 959 filers Visit website Investor relations